Eton Pharmaceuticals, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Eton Pharmaceuticals, Inc. (ETON) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 25.21 million shares for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-16.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-03-16
- Eton Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 25.29M shares, a 6.11% increase year-over-year.
- Eton Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 25.28M shares, a 20.06% increase year-over-year.
- Eton Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 23.83M shares, a 32.94% increase year-over-year.
- Eton Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 21.05M shares, a 17.75% increase year-over-year.
- Eton Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 25.21M shares, a 19.98% increase from fiscal 2020.
- Eton Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 21.01M shares, a 18.29% increase from fiscal 2019.
- Eton Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 17.76M shares, a 176.73% increase from fiscal 2018.
- Eton Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 6.42M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 5 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 8 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | 25.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | 25.28M shares derived: average of 2 quarters · filed 2022-03-16 | 25.21M shares 10-K · filed 2022-03-16 | |||||||
| 2021-09-30 | 25.28M shares 10-Q · filed 2021-11-16 | 25.18M shares 10-Q · filed 2021-11-16 | ||||||||
| 2020-12-31 | 23.83M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | 22.44M shares derived: average of 2 quarters · filed 2022-03-16 | 14.97M shares derived: average of 3 quarters · filed 2022-03-16 | 21.01M shares 10-K · filed 2022-03-16 | 21.01M shares 10-K · filed 2021-03-16 | |||||
| 2020-09-30 | 21.05M shares 10-Q · filed 2021-11-16 | 21.05M shares 10-Q · filed 2020-11-12 | 10.54M shares derived: average of 2 quarters · filed 2021-11-16 | 20.07M shares 10-Q · filed 2021-11-16 | 20.07M shares 10-Q · filed 2020-11-12 | 14.29M shares derived: average of 4 quarters · filed 2021-11-16 | ||||
| 2020-06-30 | 21.00K shares 10-Q · filed 2020-08-12 | 19.57K shares 10-Q · filed 2020-08-12 | 12.03M shares derived: average of 3 quarters · filed 2020-08-12 | 13.49M shares derived: average of 4 quarters · filed 2020-11-12 | ||||||
| 2020-03-31 | 18.14M shares 10-Q · filed 2020-05-14 | 18.03M shares derived: average of 2 quarters · filed 2020-05-14 | 17.98M shares derived: average of 3 quarters · filed 2020-11-12 | 13.49M shares derived: average of 4 quarters · filed 2020-11-12 | ||||||
| 2019-12-31 | 17.92M shares 10-K · filed 2020-03-05 | 17.90M shares derived: average of 2 quarters · filed 2020-11-12 | 11.94M shares derived: average of 3 quarters · filed 2020-11-12 | 17.76M shares 10-K · filed 2022-03-16 | 17.76M shares 10-K · filed 2020-03-05 | |||||
| 2019-09-30 | 17.88M shares 10-Q · filed 2020-11-12 | 8.95M shares derived: average of 2 quarters · filed 2020-11-12 | 17.71M shares 10-Q · filed 2020-11-12 | 11.76M shares derived: average of 4 quarters · filed 2020-11-12 | ||||||
| 2019-06-30 | 17.73K shares 10-Q · filed 2020-08-12 | 17.73M shares 10-Q · filed 2019-08-06 | 17.62K shares 10-Q · filed 2020-08-12 | 17.62M shares 10-Q · filed 2019-08-06 | 9.72M shares derived: average of 3 quarters · filed 2020-08-12 | 8.69M shares derived: average of 4 quarters · filed 2020-08-12 | ||||
| 2019-03-31 | 17.50M shares 10-Q · filed 2020-05-14 | 14.57M shares derived: average of 2 quarters · filed 2020-05-14 | 11.59M shares derived: average of 3 quarters · filed 2020-05-14 | 9.89M shares derived: average of 4 quarters · filed 2020-05-14 | ||||||
| 2018-12-31 | 11.64M shares 10-K · filed 2020-03-05 | 8.63M shares derived: average of 2 quarters · filed 2020-03-05 | 7.35M shares derived: average of 3 quarters · filed 2020-03-05 | 6.42M shares 10-K · filed 2021-03-16 | ||||||
| 2018-09-30 | 5.62M shares 10-K · filed 2020-03-05 | 5.20M shares derived: average of 2 quarters · filed 2020-03-05 | 4.66M shares 10-Q · filed 2019-11-14 | |||||||
| 2018-06-30 | 4.79M shares 10-K · filed 2020-03-05 | 4.17M shares 10-Q · filed 2019-08-06 | ||||||||
| 2018-03-31 | 3.55M shares 10-K · filed 2020-03-05 | |||||||||
| 2017-12-31 | 3.45M shares 10-K · filed 2020-03-05 | |||||||||
| 2017-09-30 | 3.50M shares 10-Q · filed 2018-12-20 | 3.41M shares 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |